Skip to main content
. 2021 Jan 29;3:100049. doi: 10.1016/j.lanepe.2021.100049

Fig. 4.

Fig 4

Overall survival (OS) and 5-year OS rate (panel A), with 12-months landmark (panel B), and progression-free survival (PFS) and 5-year PFS rate (panel C). Data shown from mCRC diagnosis in R0/1-resected, R2-resected or LAT, systemic therapy only, and best supportive care (BSC) groups. Hazard ratio (HR) and 95% confidence interval (CI) with systemic therapy used as reference group.